AKT1 and neoplasm: Tanespimycin, an Hsp90 inhibitor, reduces tumor cell survival in vitro by affecting the IL-6 receptor and elements of the PI3K/AKT and MAPK signaling pathways, through abrogation of the protective effect of BMSCs.